nach oben

Cancer and Metastasis Reviews

Erschienen in:

05.10.2023 | Review

Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?

verfasst von: Homa Fatma, Hifzur R. Siddique

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Cellular plasticity can occur naturally in an organism and is considered an adapting mechanism during the developmental stage. However, abnormal cellular plasticity is observed in different diseased conditions, including cancer. Cancer cell plasticity triggers the stimuli of epithelial-mesenchymal transition (EMT), abnormal epigenetic changes, expression of stem cell factors and implicated signaling pathways, etc., and helps in the maintenance of CSC phenotype. Conversely, CSC maintains the cancer cell plasticity, EMT, and epigenetic plasticity. EMT contributes to increased cell migration and greater diversity within tumors, while epigenetic changes, stem cell factors (OCT4, NANOG, and SOX2), and various signaling pathways allow cancer cells to maintain various phenotypes, giving rise to intra- and inter-tumoral heterogeneity. The intricate relationships between cancer cell plasticity and stem cell factors help the tumor cells adopt drug-tolerant states, evade senescence, and successfully acquire drug resistance with treatment dismissal. Inhibiting molecules/signaling pathways involved in promoting CSCs, cellular plasticity, EMT, and epigenetic plasticity might be helpful for successful cancer therapy management. This review discussed the role of cellular plasticity, EMT, and stem cell factors in tumor initiation, progression, reprogramming, and therapy resistance. Finally, we discussed how the intervention in this axis will help better manage cancers and improve patient survivability.

Graphical abstract

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Vineis, P., Schatzkin, A., & Potter, J. D. (2010). Models of carcinogenesis: An overview. Carcinogenesis, 31(10), 1703–1709. https://doi.org/10.1093/carcin/bgq087CrossRefPubMedPubMedCentral

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMed

Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059CrossRefPubMed

Shen, S., & Clairambault, J. (2020). Cell plasticity in cancer cell populations. F1000Research, 9, F1000 Faculty Rev-635. https://doi.org/10.12688/f1000research.24803.1

Ferrao, P. T., Behren, A., Anderson, R. L., & Thompson, E. W. (2015). Editorial: Cellular and phenotypic plasticity in cancer. Frontiers in Oncology, 5, 171. https://doi.org/10.3389/fonc.2015.00171CrossRefPubMedPubMedCentral

Herreros-Villanueva, M., Bujanda, L., Billadeau, D. D., & Zhang, J. S. (2014). Embryonic stem cell factors and pancreatic cancer. World Journal of Gastroenterology, 20(9), 2247–2254. https://doi.org/10.3748/wjg.v20.i9.2247CrossRefPubMedPubMedCentral

Tang, F., Barbacioru, C., Bao, S., Lee, C., Nordman, E., Wang, X., Lao, K., & Surani, M. A. (2010). Tracing the derivation of embryonic stem cells from the inner cell mass by single-cell RNA-Seq analysis. Cell Stem Cell, 6(5), 468–478. https://doi.org/10.1016/j.stem.2010.03.015CrossRefPubMedPubMedCentral

Fatma, H., & Siddique, H. R. (2021). Pluripotency inducing Yamanaka factors: Role in stemness and chemoresistance of liver cancer. Expert Review of Anticancer Therapy, 21(8), 853–864. https://doi.org/10.1080/14737140.2021.1915137CrossRefPubMed

10.

Hadjimichael, C., Chanoumidou, K., Papadopoulou, N., Arampatzi, P., Papamatheakis, J., & Kretsovali, A. (2015). Common stemness regulators of embryonic and cancer stem cells. World journal of stem cells, 7(9), 1150–1184. https://doi.org/10.4252/wjsc.v7.i9.1150CrossRefPubMedPubMedCentral

11.

Fatma, H., Siddique, H. R., & Maurya, S. K. (2021). The multiple faces of NANOG in cancer: A therapeutic target to chemosensitize therapy-resistant cancers. Epigenomics, 13(23), 1885–1900. https://doi.org/10.2217/epi-2021-0228CrossRefPubMed

12.

Boumahdi, S., & de Sauvage, F. J. (2020). The great escape: Tumor cell plasticity in resistance to targeted therapy. Nature reviews. Drug Design and Discovery, 19(1), 39–56. https://doi.org/10.1038/s41573-019-0044-1CrossRef

13.

Jacquemin, V., Antoine, M., Dom, G., Detours, V., Maenhaut, C., & Dumont, J. E. (2022). Dynamic cancer cell heterogeneity: Diagnostic and therapeutic implications. Cancers, 14(2), 280. https://doi.org/10.3390/cancers14020280CrossRefPubMedPubMedCentral

14.

Dagogo-Jack, I., & Shaw, A. T. (2018). Tumour heterogeneity and resistance to cancer therapies. Nature reviews. Clinical Oncology, 15(2), 81–94. https://doi.org/10.1038/nrclinonc.2017.166CrossRefPubMed

15.

Cancer Genome Atlas Research Network. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(7216), 1061–1068. https://doi.org/10.1038/nature07385CrossRef

16.

Murugaesu, N., Wilson, G. A., Birkbak, N. J., Watkins, T., McGranahan, N., Kumar, S., Abbassi-Ghadi, N., Salm, M., Mitter, R., Horswell, S., Rowan, A., Phillimore, B., Biggs, J., Begum, S., Matthews, N., Hochhauser, D., Hanna, G. B., & Swanton, C. (2015). Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discovery, 5(8), 821–831. https://doi.org/10.1158/2159-8290.CD-15-0412CrossRefPubMedPubMedCentral

17.

Fanelli, G. N., Naccarato, A. G., & Scatena, C. (2020). Recent advances in cancer plasticity: Cellular mechanisms, surveillance strategies, and therapeutic optimization. Frontiers in Oncology, 10, 569. https://doi.org/10.3389/fonc.2020.00569CrossRefPubMedPubMedCentral

18.

Cairns, J. (1975). Mutation selection and the natural history of cancer. Nature, 255(5505), 197–200. https://doi.org/10.1038/255197a0CrossRefPubMed

19.

Nowell, P. C. (1976). The clonal evolution of tumor cell populations. Science, 194(4260), 23–28. https://doi.org/10.1126/science.959840CrossRefPubMed

20.

Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature, 481(7381), 306–313. https://doi.org/10.1038/nature10762CrossRefPubMedPubMedCentral

21.

McGranahan, N., & Swanton, C. (2017). Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell, 168(4), 613–628. https://doi.org/10.1016/j.cell.2017.01.018CrossRefPubMed

22.

Ahmed, M., & Li, L. C. (2013). Adaptation and clonal selection models of castration-resistant prostate cancer: Current perspective. International Journal of Urology : Official Journal of the Japanese Urological Association, 20(4), 362–371. https://doi.org/10.1111/iju.12005CrossRefPubMed

23.

Vaquero-Siguero, N., Schleussner, N., Volk, J., Mastel, M., Meier, J., & Jackstadt, R. (2022). Modeling colorectal cancer progression reveals niche-dependent clonal selection. Cancers, 14(17), 4260. https://doi.org/10.3390/cancers14174260CrossRefPubMedPubMedCentral

24.

Pierce, G. B., & Speers, W. C. (1988). Tumors as caricatures of the process of tissue renewal: Prospects for therapy by directing differentiation. Cancer Research, 48(8), 1996–2004.PubMed

25.

Kreso, A., & Dick, J. E. (2014). Evolution of the cancer stem cell model. Cell Stem Cell, 14(3), 275–291. https://doi.org/10.1016/j.stem.2014.02.006CrossRefPubMed

26.

Kise, K., Kinugasa-Katayama, Y., & Takakura, N. (2016). Tumor microenvironment for cancer stem cells. Advanced drug delivery reviews, 99(Pt B), 197–205. https://doi.org/10.1016/j.addr.2015.08.005CrossRefPubMed

27.

van Niekerk, G., Davids, L. M., Hattingh, S. M., & Engelbrecht, A. M. (2017). Cancer stem cells: A product of clonal evolution? International Journal of Cancer, 140(5), 993–999. https://doi.org/10.1002/ijc.30448CrossRefPubMed

28.

Cabrera, M. C., Hollingsworth, R. E., & Hurt, E. M. (2015). Cancer stem cell plasticity and tumor hierarchy. World journal of stem cells, 7(1), 27–36. https://doi.org/10.4252/wjsc.v7.i1.27CrossRefPubMedPubMedCentral

29.

Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019). Phenotypic plasticity: Driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell, 24(1), 65–78. https://doi.org/10.1016/j.stem.2018.11.011CrossRefPubMed

30.

Thankamony, A. P., Saxena, K., Murali, R., Jolly, M. K., & Nair, R. (2020). Cancer stem cell plasticity - A deadly deal. Frontiers in Molecular Biosciences, 7, 79. https://doi.org/10.3389/fmolb.2020.00079CrossRefPubMedPubMedCentral

31.

Roberts, C. M., Cardenas, C., & Tedja, R. (2019). The Role of intra-tumoral heterogeneity and its clinical relevance in epithelial ovarian cancer recurrence and metastasis. Cancers, 11(8), 1083. https://doi.org/10.3390/cancers11081083CrossRefPubMedPubMedCentral

32.

Stanta, G., & Bonin, S. (2018). Overview on clinical relevance of intra-tumor heterogeneity. Frontiers in Medicine, 5, 85. https://doi.org/10.3389/fmed.2018.00085CrossRefPubMedPubMedCentral

33.

Boyer, L. A., Lee, T. I., Cole, M. F., Johnstone, S. E., Levine, S. S., Zucker, J. P., Guenther, M. G., Kumar, R. M., Murray, H. L., Jenner, R. G., Gifford, D. K., Melton, D. A., Jaenisch, R., & Young, R. A. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells. Cell, 122(6), 947–956. https://doi.org/10.1016/j.cell.2005.08.020CrossRefPubMedPubMedCentral

34.

Cole, M. F., Johnstone, S. E., Newman, J. J., Kagey, M. H., & Young, R. A. (2008). Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells. Genes & Development, 22(6), 746–755. https://doi.org/10.1101/gad.1642408CrossRef

35.

Morris, S. A. (2016). Direct lineage reprogramming via pioneer factors; A detour through developmental gene regulatory networks. Development (Cambridge, England), 143(15), 2696–2705. https://doi.org/10.1242/dev.138263CrossRefPubMed

36.

Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., & Cui, H. (2020). Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy, 5(1), 8. https://doi.org/10.1038/s41392-020-0110-5CrossRefPubMedPubMedCentral

37.

Karamboulas, C., & Ailles, L. (2013). Developmental signaling pathways in cancer stem cells of solid tumors. Biochimica et Biophysica Acta, 1830(2), 2481–2495. https://doi.org/10.1016/j.bbagen.2012.11.008CrossRefPubMed

38.

Smith, B. A., Balanis, N. G., Nanjundiah, A., Sheu, K. M., Tsai, B. L., Zhang, Q., Park, J. W., Thompson, M., Huang, J., Witte, O. N., & Graeber, T. G. (2018). A human adult stem cell signature marks aggressive variants across epithelial cancers. Cell reports, 24(12), 3353–3366.e5. https://doi.org/10.1016/j.celrep.2018.08.062CrossRefPubMed

39.

Sneha, S., Nagare, R. P., Manasa, P., Vasudevan, S., Shabna, A., & Ganesan, T. S. (2019). Analysis of human stem cell transcription factors. Cell Reports, 21(4), 171–180. https://doi.org/10.1089/cell.2019.0005CrossRef

40.

Swain, N., Thakur, M., Pathak, J., & Swain, B. (2020). SOX2, OCT4 and NANOG: The core embryonic stem cell pluripotency regulators in oral carcinogenesis. Journal of oral and maxillofacial pathology: JOMFP, 24(2), 368–373. https://doi.org/10.4103/jomfp.JOMFP_22_20CrossRefPubMedPubMedCentral

41.

Liu, A., Yu, X., & Liu, S. (2013). Pluripotency transcription factors and cancer stem cells: small genes make a big difference. Chinese Journal of Cancer, 32(9), 483–487. https://doi.org/10.5732/cjc.012.10282CrossRefPubMedPubMedCentral

42.

Islam, Z., Ali, A. M., Naik, A., Eldaw, M., Decock, J., & Kolatkar, P. R. (2021). Transcription factors: The fulcrum between cell development and carcinogenesis. Frontiers in Oncology, 11, 681377. https://doi.org/10.3389/fonc.2021.681377CrossRefPubMedPubMedCentral

43.

He, Z., He, J., & Xie, K. (2023). KLF4 transcription factor in tumorigenesis. Cell Death & Disease, 9(1), 118. https://doi.org/10.1038/s41420-023-01416-yCrossRef

44.

Qi, X. T., Li, Y. L., Zhang, Y. Q., Xu, T., Lu, B., Fang, L., Gao, J. Q., Yu, L. S., Zhu, D. F., Yang, B., He, Q. J., & Ying, M. D. (2019). KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells. Acta Pharmacologica Sinica, 40(4), 546–555. https://doi.org/10.1038/s41401-018-0050-6CrossRefPubMed

45.

Ma, C., Wang, F., Han, B., Zhong, X., Si, F., Ye, J., Hsueh, E. C., Robbins, L., Kiefer, S. M., Zhang, Y., Hunborg, P., Varvares, M. A., Rauchman, M., & Peng, G. (2018). SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex. Molecular Cancer, 17(1), 78. https://doi.org/10.1186/s12943-018-0824-yCrossRefPubMedPubMedCentral

46.

Yang, F., Cui, P., Lu, Y., & Zhang, X. (2019). Requirement of the transcription factor YB-1 for maintaining the stemness of cancer stem cells and reverting differentiated cancer cells into cancer stem cells. Stem Cell Research & Therapy, 10(1), 233. https://doi.org/10.1186/s13287-019-1360-4CrossRef

47.

Gong, X., Liu, W., Wu, L., Ma, Z., Wang, Y., Yu, S., Zhang, J., Xie, H., Wei, G., Ma, F., Lu, L., & Chen, L. (2018). Transcriptional repressor GATA binding 1-mediated repression of SRY-box 2 expression suppresses cancer stem cell functions and tumor initiation. The Journal of Biological Chemistry, 293(48), 18646–18654. https://doi.org/10.1074/jbc.RA118.003983CrossRefPubMedPubMedCentral

48.

Safa, A. R., Saadatzadeh, M. R., Cohen-Gadol, A. A., Pollok, K. E., & Bijangi-Vishehsaraei, K. (2015). Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes & diseases, 2(2), 152–163. https://doi.org/10.1016/j.gendis.2015.02.001CrossRef

49.

Praharaj, P. P., Panigrahi, D. P., Bhol, C. S., Patra, S., Mishra, S. R., Mahapatra, K. K., Behera, B. P., Singh, A., Patil, S., & Bhutia, S. K. (2021). Mitochondrial rewiring through mitophagy and mitochondrial biogenesis in cancer stem cells: A potential target for anti-CSC cancer therapy. Cancer Letters, 498, 217–228. https://doi.org/10.1016/j.canlet.2020.10.036CrossRefPubMed

50.

Patil, K., Khan, F. B., Akhtar, S., Ahmad, A., & Uddin, S. (2021). The plasticity of pancreatic cancer stem cells: Implications in therapeutic resistance. Cancer Metastasis Reviews, 40(3), 691–720. https://doi.org/10.1007/s10555-021-09979-xCrossRefPubMedPubMedCentral

51.

Li, Y., Wang, Z., Ajani, J. A., & Song, S. (2021). Drug resistance and cancer stem cells. Cell Communication and Signaling: CCS, 19(1), 19. https://doi.org/10.1186/s12964-020-00627-5CrossRefPubMedPubMedCentral

52.

Paul, R., Dorsey, J. F., & Fan, Y. (2022). Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications. Pharmacology & Therapeutics, 231, 107985. https://doi.org/10.1016/j.pharmthera.2021.107985CrossRef

53.

Lu, Y., Zhu, Y., Deng, S., Chen, Y., Li, W., Sun, J., & Xu, X. (2021). Targeting the sonic hedgehog pathway to suppress the expression of the cancer stem cell (CSC)-related transcription factors and CSC-driven thyroid tumor growth. Cancers, 13(3), 418. https://doi.org/10.3390/cancers13030418CrossRefPubMedPubMedCentral

54.

Fendler, A., Bauer, D., Busch, J., Jung, K., Wulf-Goldenberg, A., Kunz, S., Song, K., Myszczyszyn, A., Elezkurtaj, S., Erguen, B., Jung, S., Chen, W., & Birchmeier, W. (2020). Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nature Communications, 11(1), 929. https://doi.org/10.1038/s41467-020-14700-7CrossRefPubMedPubMedCentral

55.

Aparicio, L. A., Blanco, M., Castosa, R., Concha, Á., Valladares, M., Calvo, L., & Figueroa, A. (2015). Clinical implications of epithelial cell plasticity in cancer progression. Cancer Letters, 366(1), 1–10. https://doi.org/10.1016/j.canlet.2015.06.007CrossRefPubMed

56.

Kumar, V. E., Nambiar, R., De Souza, C., Nguyen, A., Chien, J., & Lam, K. S. (2022). Targeting epigenetic modifiers of tumor plasticity and cancer stem cell behavior. Cells, 11(9), 1403. https://doi.org/10.3390/cells1109140357CrossRefPubMedPubMedCentral

57.

da Silva-Diz, V., Lorenzo-Sanz, L., Bernat-Peguera, A., Lopez-Cerda, M., & Muñoz, P. (2018). Cancer cell plasticity: Impact on tumor progression and therapy response. Seminars in Cancer Biology, 53, 48–58. https://doi.org/10.1016/j.semcancer.2018.08.009CrossRefPubMed

58.

Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019). Cellular plasticity in cancer. Cancer Discovery, 9(7), 837–851. https://doi.org/10.1158/2159-8290.CD-19-0015CrossRefPubMedPubMedCentral

59.

Warrier, N. M., Kelkar, N., Johnson, C. T., Govindarajan, T., Prabhu, V., & Kumar, P. (2023). Understanding cancer stem cells and plasticity: Towards better therapeutics. European Journal of Cell Biology, 102(2), 151321. https://doi.org/10.1016/j.ejcb.2023.151321CrossRefPubMed

60.

Baram, T., Rubinstein-Achiasaf, L., Ben-Yaakov, H., & Ben-Baruch, A. (2021). Inflammation-driven breast tumor cell plasticity: Stemness/EMT, therapy resistance and dormancy. Frontiers in Oncology, 10, 614468. https://doi.org/10.3389/fonc.2020.614468CrossRefPubMedPubMedCentral

61.

Guo, H., Zeng, H., Fu, C., Huang, J., Lu, J., Hu, Y., Zhou, Y., Luo, L., Zhang, Y., Zhang, L., Chen, J., & Zeng, Q. (2021). Identification of sitogluside as a potential skin-pigmentation-reducing agent through network pharmacology. Oxidative Medicine and Cellular Longevity, 2021, 4883398. https://doi.org/10.1155/2021/4883398CrossRefPubMedPubMedCentral

62.

Ray, T., Ryusaki, T., & Ray, P. S. (2021). Therapeutically targeting cancers that overexpress FOXC1: A transcriptional driver of cell plasticity, partial EMT, and cancer metastasis. Frontiers in Oncology, 11, 721959. https://doi.org/10.3389/fonc.2021.721959CrossRefPubMedPubMedCentral

63.

Friedmann-Morvinski, D. (2014). Glioblastoma heterogeneity and cancer cell plasticity. Critical Reviews in Oncogenesis, 19(5), 327–336. https://doi.org/10.1615/critrevoncog.2014011777CrossRefPubMed

64.

Lee, C. C., Lin, J. C., Hwang, W. L., Kuo, Y. J., Chen, H. K., Tai, S. K., Lin, C. C., & Yang, M. H. (2018). Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization. Nature Communications, 9(1), 3763. https://doi.org/10.1038/s41467-018-06268-0CrossRefPubMedPubMedCentral

65.

Chaffer, C. L., San Juan, B. P., Lim, E., & Weinberg, R. A. (2016). EMT, cell plasticity and metastasis. Cancer Metastasis Reviews, 35(4), 645–654. https://doi.org/10.1007/s10555-016-9648-7CrossRefPubMed

66.

Savagner, P. (2015). Epithelial-mesenchymal transitions: from cell plasticity to concept elasticity. Current Topics in Developmental Biology, 112, 273–300. https://doi.org/10.1016/bs.ctdb.2014.11.021CrossRefPubMed

67.

Xu, Y., Lee, D. K., Feng, Z., Xu, Y., Bu, W., Li, Y., Liao, L., & Xu, J. (2017). Breast tumor cell-specific knockout of Twist1 inhibits cancer cell plasticity, dissemination, and lung metastasis in mice. Proceedings of the National Academy of Sciences of the United States of America, 114(43), 11494–11499. https://doi.org/10.1073/pnas.1618091114CrossRefPubMedPubMedCentral

68.

Krebs, A. M., Mitschke, J., Lasierra Losada, M., Schmalhofer, O., Boerries, M., Busch, H., Boettcher, M., Mougiakakos, D., Reichardt, W., Bronsert, P., Brunton, V. G., Pilarsky, C., Winkler, T. H., Brabletz, S., Stemmler, M. P., & Brabletz, T. (2017). The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nature Cell Biology, 19(5), 518–529. https://doi.org/10.1038/ncb3513CrossRefPubMed

69.

Zhou, W., Ye, X. L., Xu, J., Cao, M. G., Fang, Z. Y., Li, L. Y., Guan, G. H., Liu, Q., Qian, Y. H., & Xie, D. (2017). The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b. Science Signaling, 10(483), eaak9557. https://doi.org/10.1126/scisignal.aak9557CrossRefPubMed

70.

Fan, C., Wang, Q., Kuipers, T. B., Cats, D., Iyengar, P. V., Hagenaars, S. C., Mesker, W. E., Devilee, P., Tollenaar, R. A. E. M., Mei, H., & Ten Dijke, P. (2023). LncRNA LITATS1 suppresses TGF-β-induced EMT and cancer cell plasticity by potentiating TβRI degradation. The EMBO journal, 42(10), e112806. https://doi.org/10.15252/embj.2022112806CrossRefPubMedPubMedCentral

71.

Lüönd, F., Tiede, S., & Christofori, G. (2021). Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. British Journal of Cancer, 125(2), 164–175. https://doi.org/10.1038/s41416-021-01328-7CrossRefPubMedPubMedCentral

72.

Singh, S. K., Chen, N. M., Hessmann, E., Siveke, J., Lahmann, M., Singh, G., Voelker, N., Vogt, S., Esposito, I., Schmidt, A., Brendel, C., Stiewe, T., Gaedcke, J., Mernberger, M., Crawford, H. C., Bamlet, W. R., Zhang, J. S., Li, X. K., Smyrk, T. C., et al. (2015). Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. The EMBO journal, 34(4), 517–530. https://doi.org/10.15252/embj.201489574CrossRefPubMedPubMedCentral

73.

Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017). Epigenetic plasticity and the hallmarks of cancer. Science, 357(6348), eaal2380. https://doi.org/10.1126/science.aal2380CrossRefPubMedPubMedCentral

74.

Burdziak, C., Alonso-Curbelo, D., Walle, T., Reyes, J., Barriga, F. M., Haviv, D., Xie, Y., Zhao, Z., Zhao, C. J., Chen, H. A., Chaudhary, O., Masilionis, I., Choo, Z. N., Gao, V., Luan, W., Wuest, A., Ho, Y. J., Wei, Y., Quail, D. F., et al. (2023). Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis. Science, 380(6645), eadd5327. https://doi.org/10.1126/science.add5327CrossRefPubMedPubMedCentral

75.

Bedi, U., Mishra, V. K., Wasilewski, D., Scheel, C., & Johnsen, S. A. (2014). Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget, 5(8), 2016–2029. https://doi.org/10.18632/oncotarget.1875CrossRefPubMedPubMedCentral

76.

Anatskaya, O. V., & Vinogradov, A. E. (2022). Polyploidy and Myc proto-oncogenes promote stress adaptation via epigenetic plasticity and gene regulatory network rewiring. International Journal of Molecular Sciences, 23(17), 9691. https://doi.org/10.3390/ijms23179691CrossRefPubMedPubMedCentral

77.

De Smedt, E., Lui, H., Maes, K., De Veirman, K., Menu, E., Vanderkerken, K., & De Bruyne, E. (2018). The epigenome in multiple myeloma: Impact on tumor cell plasticity and drug response. Frontiers in Oncology, 8, 566. https://doi.org/10.3389/fonc.2018.00566CrossRefPubMedPubMedCentral

78.

Tam, W. L., & Weinberg, R. A. (2013). The epigenetics of epithelial-mesenchymal plasticity in cancer. Nature Medicine, 19(11), 1438–1449. https://doi.org/10.1038/nm.3336CrossRefPubMedPubMedCentral

79.

He, R., Xhabija, B., Gopi, L. K., Kurup, J. T., Xu, Z., Liu, Z., & Kidder, B. L. (2022). H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity. Oncogene, 41(21), 2958–2972. https://doi.org/10.1038/s41388-022-02311-zCrossRefPubMedPubMedCentral

80.

Yao, J., Chen, J., Li, L. Y., & Wu, M. (2020). Epigenetic plasticity of enhancers in cancer. Transcription, 11(1), 26–36. https://doi.org/10.1080/21541264.2020.1713682CrossRefPubMedPubMedCentral

81.

Fagnocchi, L., Poli, V., & Zippo, A. (2018). Enhancer reprogramming in tumor progression: A new route towards cancer cell plasticity. Cellular and Molecular Life Sciences: CMLS, 75(14), 2537–2555. https://doi.org/10.1007/s00018-018-2820-1CrossRefPubMed

82.

Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S. Y. (2020). Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics, 10(19), 8721–8743. https://doi.org/10.7150/thno.41648CrossRefPubMedPubMedCentral

83.

Huang, J., Liu, K., Song, D., Ding, M., Wang, J., Jin, Q., & Ni, J. (2016). Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells. Cancer Science, 107(3), 242–249. https://doi.org/10.1111/cas.12864CrossRefPubMedPubMedCentral

84.

Huang, C. P., Tsai, M. F., Chang, T. H., et al. (2013). ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Letters, 328(1), 144–151. https://doi.org/10.1016/j.canlet.2012.08.021CrossRefPubMed

85.

Shlush, L. I., Mitchell, A., Heisler, L., Abelson, S., Ng, S. W. K., Trotman-Grant, A., Medeiros, J. J. F., Rao-Bhatia, A., Jaciw-Zurakowsky, I., Marke, R., McLeod, J. L., Doedens, M., Bader, G., Voisin, V., Xu, C., McPherson, J. D., Hudson, T. J., Wang, J. C. Y., Minden, M. D., et al. (2017). Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature, 547(7661), 104–108. https://doi.org/10.1038/nature22993CrossRefPubMed

86.

Steinbichler, T. B., Dudás, J., Skvortsov, S., Ganswindt, U., Riechelmann, H., & Skvortsova, I. I. (2018). Therapy resistance mediated by cancer stem cells. Seminars in Cancer Biology, 53, 156–167. https://doi.org/10.1016/j.semcancer.2018.11.006CrossRefPubMed

87.

Cojoc, M., Mäbert, K., Muders, M. H., & Dubrovska, A. (2015). A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Seminars in Cancer Biology, 31, 16–27. https://doi.org/10.1016/j.semcancer.2014.06.004CrossRefPubMed

88.

Zhou, H. M., Zhang, J. G., Zhang, X., & Li, Q. (2021). Targeting cancer stem cells for reversing therapy resistance: Mechanism, signaling, and prospective agents. Signal Transduction and Targeted Therapy, 6(1), 62. https://doi.org/10.1038/s41392-020-00430-1CrossRefPubMedPubMedCentral

89.

Mohiuddin, I. S., Wei, S. J., & Kang, M. H. (2020). Role of OCT4 in cancer stem-like cells and chemotherapy resistance. Biochimica et biophysica acta. Molecular basis of disease, 1866(4), 165432. https://doi.org/10.1016/j.bbadis.2019.03.005CrossRefPubMed

90.

Liau, B. B., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J., Shareef, S. J., Najm, F. J., van Galen, P., Wakimoto, H., Cahill, D. P., Rich, J. N., Aster, J. C., Suvà, M. L., Patel, A. P., et al. (2017). Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell stem cell, 20(2), 233–246.e7. https://doi.org/10.1016/j.stem.2016.11.003CrossRefPubMed

91.

Rabé, M., Dumont, S., Álvarez-Arenas, A., Janati, H., Belmonte-Beitia, J., Calvo, G. F., Thibault-Carpentier, C., Séry, Q., Chauvin, C., Joalland, N., Briand, F., Blandin, S., Scotet, E., Pecqueur, C., Clairambault, J., Oliver, L., Perez-Garcia, V., Nadaradjane, A., Cartron, P. F., et al. (2020). Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. Cell Death & Disease, 11(1), 19. https://doi.org/10.1038/s41419-019-2200-2CrossRef

92.

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., Wong, K. K., Brandstetter, K., Wittner, B., Ramaswamy, S., Classon, M., & Settleman, J. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141(1), 69–80. https://doi.org/10.1016/j.cell.2010.02.027CrossRefPubMedPubMedCentral

93.

Shen, S., Faouzi, S., Bastide, A., Martineau, S., Malka-Mahieu, H., Fu, Y., Sun, X., Mateus, C., Routier, E., Roy, S., Desaubry, L., André, F., Eggermont, A., David, A., Scoazec, J. Y., Vagner, S., & Robert, C. (2019). An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. Nature Communications, 10(1), 5713. https://doi.org/10.1038/s41467-019-13360-6CrossRefPubMedPubMedCentral

94.

Sánchez-Danés, A., Larsimont, J. C., Liagre, M., Muñoz-Couselo, E., Lapouge, G., Brisebarre, A., Dubois, C., Suppa, M., Sukumaran, V., Del Marmol, V., Tabernero, J., & Blanpain, C. (2018). A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Nature, 562(7727), 434–438. https://doi.org/10.1038/s41586-018-0603-3CrossRefPubMedPubMedCentral

95.

De Angelis, M. L., Francescangeli, F., La Torre, F., & Zeuner, A. (2019). Stem cell plasticity and dormancy in the development of cancer therapy resistance. Frontiers in Oncology, 9, 626. https://doi.org/10.3389/fonc.2019.00626CrossRefPubMedPubMedCentral

96.

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020). Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase. Cancer & metabolism, 8, 19. https://doi.org/10.1186/s40170-020-00226-5CrossRef

97.

Lorenzo-Sanz, L., & Muñoz, P. (2019). Tumor-infiltrating immunosuppressive cells in cancer-cell plasticity, tumor progression and therapy response. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 12(2-3), 119–132. https://doi.org/10.1007/s12307-019-00232-2CrossRefPubMed

98.

Wang, J. Y., Ma, J., Lin, Y. N., Wang, J., Shen, H., Gui, F. M., Han, C., Li, Q. H., Song, Z., & Wang, X. J. (2017). Zhonghua xue ye xue za zhi. Zhonghua Xueyexue Zazhi, 38(3), 192–197. https://doi.org/10.3760/cma.j.issn.0253-2727.2017.03.004CrossRefPubMed

99.

Tanabe, S., Quader, S., Cabral, H., & Ono, R. (2020). Interplay of EMT and CSC in cancer and the potential therapeutic strategies. Frontiers in Pharmacology, 11, 904. https://doi.org/10.3389/fphar.2020.00904CrossRefPubMedPubMedCentral

100.

Jeng, K. S., Chang, C. F., & Lin, S. S. (2020). Sonic hedgehog signaling in organogenesis, tumors, and tumor microenvironments. International Journal of Molecular Sciences, 21(3), 758. https://doi.org/10.3390/ijms21030758CrossRefPubMedPubMedCentral

101.

Gong, L., Yan, Q., Zhang, Y., Fang, X., Liu, B., & Guan, X. (2019). Cancer cell reprogramming: a promising therapy converting malignancy to benignity. Cancer communications, 39(1), 48. https://doi.org/10.1186/s40880-019-0393-5CrossRefPubMedPubMedCentral

102.

Srivastava, D., & DeWitt, N. (2016). In vivo cellular reprogramming: The next generation. Cell, 166(6), 1386–1396. https://doi.org/10.1016/j.cell.2016.08.055CrossRefPubMedPubMedCentral

103.

Lin, S. L., Chang, D. C., Chang-Lin, S., Lin, C. H., Wu, D. T., Chen, D. T., & Ying, S. Y. (2008). Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA, 14(10), 2115–2124. https://doi.org/10.1261/rna.1162708CrossRefPubMedPubMedCentral

Titel: Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?
verfasst von: Homa Fatma
Hifzur R. Siddique
Publikationsdatum: 05.10.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2024
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10144-9

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?

Abstract

Graphical abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Glucocorticoid receptor: a harmonizer of cellular plasticity in breast cancer—directs the road towards therapy resistance, metastatic progression and recurrence

Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review

Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance

Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals

Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance

Sam68 is a druggable vulnerability point in cancer stem cells

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie